Study on Azenosertib (ZN-c3) for Patients with Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Inclusion Criteria

• Must be 18 years or older.
• Have high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
• Tumors must test positive for Cyclin E1 protein using a specific test.
• Cancer must be resistant to platinum-based treatments.
• Have had 1 to 3 previous treatment regimens (up to 4 if previously treated with mirvetuximab).
• Must have received bevacizumab, if eligible.
• Must have received a PARP inhibitor if there is a BRCA 1/2 mutation or HRD, if eligible.
• Must have received mirvetuximab, if eligible.
• Must have measurable disease according to specific criteria.
• Must have adequate blood and organ function.
• Must have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.

Exclusion Criteria

• Cancer that did not respond to initial platinum-based treatment.
• Recent major surgery, hospitalization, or certain treatments within specified time frames before starting the study.
• Previous treatment with ZN-c3 or similar drugs.
• Serious medical conditions, including unstable brain metastases, heart failure, severe infections, or significant gastrointestinal issues.
• Unresolved side effects from previous treatments, except for mild neuropathy, hair loss, or skin changes.
• Pregnant or breastfeeding women, or women who could become pregnant and have a positive pregnancy test.
• History of another cancer in the past 2 years, unless treated and disease-free.
• Known immunocompromised status or active hepatitis B or C infection.
• Judged unsuitable for the study by the investigator.
• Previous extensive radiation therapy affecting a large portion of the bone marrow.